Rafferty Asset Management
MRNA icon

Rafferty Asset Management’s Moderna MRNA Stock Holding History

Rafferty Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.84M Sell
111,906
-2,288
-2% -$118K 0.02% 306
2026
Q1 		$5.8M Sell
114,194
-123,637
-52% -$5.77M 0.02% 325
2025
Q4 		$7.01M Sell
237,831
-143,101
-38% -$3.89M 0.02% 333
2025
Q3 		$9.84M Sell
380,932
-13,667
-3% -$381K 0.03% 288
2025
Q2 		$10.9M Buy
394,599
+45,740
+13% +$1.2M 0.04% 254
2025
Q1 		$9.89M Sell
348,859
-7,236
-2% -$257K 0.04% 264
2024
Q4 		$14.8M Sell
356,095
-104,869
-23% -$5.01M 0.05% 213
2024
Q3 		$30.8M Buy
460,964
+199,204
+76% +$18.3M 0.11% 108
2024
Q2 		$31.1M Buy
261,760
+18,598
+8% +$2.35M 0.12% 101
2024
Q1 		$25.9M Sell
243,162
-28,167
-10% -$2.84M 0.1% 113
2023
Q4 		$27M Buy
271,329
+80,487
+42% +$6.77M 0.11% 108
2023
Q3 		$19.7M Buy
190,842
+33,694
+21% +$3.76M 0.12% 116
2023
Q2 		$19.1M Buy
157,148
+39,299
+33% +$5.24M 0.11% 119
2023
Q1 		$18.1M Buy
117,849
+16,136
+16% +$2.66M 0.12% 117
2022
Q4 		$18.3M Sell
101,713
-18,924
-16% -$3.09M 0.15% 109
2022
Q3 		$14.3M Buy
120,637
+29,601
+33% +$4.49M 0.15% 100
2022
Q2 		$13M Buy
91,036
+2,780
+3% +$397K 0.12% 100
2022
Q1 		$15.2M Buy
88,256
+40,968
+87% +$6.9M 0.09% 135
2021
Q4 		$12M Buy
47,288
+19,369
+69% +$5.66M 0.06% 159
2021
Q3 		$10.7M Sell
27,919
-2,579
-8% -$951K 0.07% 155
2021
Q2 		$7.17M Sell
30,498
-18,565
-38% -$3.32M 0.05% 236
2021
Q1 		$6.42M Buy
49,063
+16,706
+52% +$2.42M 0.04% 238
2020
Q4 		$3.38M Sell
32,357
-40,865
-56% -$4.13M 0.03% 332
2020
Q3 		$5.18M Buy
73,222
+57,565
+368% +$4.01M 0.06% 177
2020
Q2 		$1M Sell
15,657
-3,490
-18% -$191K 0.01% 541
2020
Q1 		$573K Sell
19,147
-143,597
-88% -$3.3M 0.02% 308
2019
Q4 		$3.18M Buy
+162,744
New +$2.89M 0.05% 211

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Rafferty Asset Management's MRNA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Moderna (MRNA) stake by 2% in Q2 2026, selling an estimated $118K and leaving 111,906 shares worth $7.84M. The position accounts for 0.02% of the portfolio, ranked #306.

Rafferty Asset Management first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $31.1M in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Rafferty Asset Management held 111,906 shares of Moderna worth $7.84M as of Q2 2026.
  • Rafferty Asset Management sold 2,288 Moderna shares in Q2 2026, an estimated $118K.
  • Moderna made up 0.02% of Rafferty Asset Management's portfolio in Q2 2026, its #306 holding.
  • Rafferty Asset Management first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • Rafferty Asset Management's Moderna position peaked at $31.1M in Q2 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.